Global and United States Cancer Biomarkers Market

Global and United States Cancer Biomarkers Market Report & Forecast 2023-2029

Global and United States Cancer Biomarkers Market

Global and United States Cancer Biomarkers Market Report & Forecast 2023-2029


Market by End User (Office Building Construction, Retail Construction, Hospitality Construction, Institutional Construction, Other End Users), by North America (United States, Canada, Mexico), by South America (Brazil, Argentina, Rest of South America), by Europe (United Kingdom, Germany, France, Italy, Spain, Russia, Benelux, Nordics, Rest of Europe), by Middle East & Africa (Turkey, Israel, GCC, North Africa, South Africa, Rest of Middle East & Africa), by Asia Pacific (China, India, Japan, South Korea, ASEAN, Oceania, Rest of Asia Pacific) Forecast - is a comprehensive report that provides insights into the market dynamics, including the key drivers, challenges, and opportunities shaping the industry landscape. It also delves into the competitive landscape, highlighting the major players and their strategies.


Exclusive deal : 20% Instant discount on Direct purchases! Don't wait—claim your discount today!

The research time span covered by the report is from 2018 to 2029; it provides an overview of the Global Cancer Biomarkers Market and also provides a deeper in-depth segmentation of the market by regions, product type and downstream industries.

The global Cancer Biomarkers market size in 2022 is 13240.0 million US dollars, and it is expected to be XX million US dollars by 2029, with a compound annual growth rate of 13.60% expected in 2023-2029.

MARKET COMPETITIVE LANDSCAPE:

The main players in the Cancer Biomarkers market include F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Abbott (U.S.), QIAGEN (Germany), and PerkinElmer, Inc. (U.S.). The share of the top 3 players in the Cancer Biomarkers market is XX%.

REGION SHARE:

The report covers the market size information of North America, Europe, Asia Pacific, Latin America, Middle East and Africa, and North America accounted for XX%, Europe accounted for XX% of Cancer Biomarkers market, and Asia Pacific accounted for XX%.

SEGMENT OVERVIEW:

The report segments the market by Type and Application. Consumables accounted for XX% of Cancer Biomarkers market in 2022. Services share of XX%.

OMICS accounted for XX% of the Cancer Biomarkers market in 2022. Imaging Technology accounts for XX%.

For competitive landscape, prominent players with considerable market shares are comprehensively analyzed in this report. With information regarding the concentration ratio and detailed data reflecting the market performance of each player shared, the readers can acquire a holistic view of the competitive situation and a better understanding of their competitors.

As the COVID-19 takes over the world, we are continuously tracking the changes in the markets. We analyzed the impact of the pandemic in detail, along with other key factors, such as macro-economy, regional conflicts, industry related news and policies. Meanwhile, market investment scenario, technology status and developments, supply chain challenges, among other essential research elements are all covered.

Key Factors Considered:

COVID-19

The report describes the market scenario during and post the pandemic in the vision of upstream, major market participants, downstream major customers, etc. Other aspects, such as changes in consumer behavior, demand, transport capacity, trade flow under COVID-19, have also been taken into consideration during the process of the research.

Regional Conflict / Russia-Ukraine War

The report also presents the impact of regional conflict on this market in an effort to aid the readers to understand how the market has been adversely influenced and how it's going to evolve in the years to come.

Challenges & Opportunities

Factors that may help create opportunities and boost profits for market players, as well as challenges that may restrain or even pose a threat to the development of the players, are revealed in the report, which can shed a light on strategic decisions and implementation.

The life sciences industry grows and continues to advance, driving innovation and improving healthcare outcomes for individuals around the world.

Artificial Intelligence (AI) and Machine Learning (ML): AI and ML technologies are increasingly being employed in life sciences research and development. They aid in drug discovery, optimizing clinical trials, analyzing vast amounts of biological data, and identifying patterns that can lead to breakthroughs in understanding diseases and developing new therapies.

Digital Health Technologies: Digital health technologies have seen rapid growth, especially in areas like telemedicine, wearable devices, and mobile health applications. These technologies enable remote patient monitoring, facilitate better healthcare access, and empower individuals to manage their health more effectively.

Wearable Devices and Remote Monitoring: Wearable devices, such as smartwatches and fitness trackers, have become more sophisticated, enabling continuous monitoring of vital signs and health parameters. These devices offer opportunities for early detection of health issues and improved management of chronic conditions.

Market Data Breakdown by Regions

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Asia Pacific

China

Japan

South Korea

India

Southeast Asia

Australia

Latin America

Brazil

Argentina

Mexico

MEA

Saudi Arabia

UAE

Turkey

Some prominent players in the market includes:

F. Hoffmann-La Roche Ltd. (Switzerland)

Thermo Fisher Scientific Inc. (U.S.)

Abbott (U.S.)

QIAGEN (Germany)

PerkinElmer, Inc. (U.S.)

Merck KGaA (Germany)

Bio-Rad Laboratories, Inc. (U.S.)

Enzo Biochem, Inc. (U.S.)

Charles River Laboratories (U.S.)

Eurofins Scientific (Luxembourg)

Agilent Technologies, Inc. (U.S.)

Bruker (U.S.)

Siemens (U.S.)

Epigenomics AG (Germany)

General Electric (U.S.)

Market Data Breakdown by Type

Consumables

Services

Software

Growth Hormone Therapy

Market Data Breakdown by Applications

OMICS

Imaging Technology

Immunoassays

Cytogenetics

Bioinformatics

Table of Content

1 Study Coverage

1.1 Cancer Biomarkers Product Introduction

1.2 Global Cancer Biomarkers Outlook 2018 VS 2023 VS 2029

1.3 United States Cancer Biomarkers Outlook 2018 VS 2023 VS 2029

1.4 Cancer Biomarkers Market Size, United States VS Global, 2018-2029

1.4.1 The Market Share of United States Cancer Biomarkers in Global, 2018-2029

1.4.2 The Growth Rate of Cancer Biomarkers Market Size, United States VS Global, 2018 VS 2023 VS 2029

1.5 Cancer Biomarkers Market Dynamics

1.5.1 Cancer Biomarkers Market Trends

1.5.2 Cancer Biomarkers Market Drivers

1.5.3 Cancer Biomarkers Market Challenges

1.5.4 Cancer Biomarkers Market Restraints

1.6 Study Objectives

1.7 Years Considered

1.8 Coronavirus Disease (COVID-19) Impact on Global

2 Global Cancer Biomarkers Competitor Landscape by Company

2.1 Global Cancer Biomarkers Market Size by Company

2.1.1 Top Global Cancer Biomarkers Player Ranked by Revenue (2023)

2.1.2 Global Cancer Biomarkers Revenue by Player (2018-2023)

2.2 Global Cancer Biomarkers Concentration Ratio (CR)

2.2.1 Cancer Biomarkers Market Concentration Ratio (CR) (2018-2023)

2.2.2 Global Top 3 and Top 6 Largest Players of Cancer Biomarkers in 2023

2.3 Global Cancer Biomarkers Business Distribution, Business Type

2.3.1 Global Cancer Biomarkers Players, Headquarters and Distribution

2.3.2 Players Cancer Biomarkers Business Type

2.3.3 Date of International Players Enter into Cancer Biomarkers Market

2.4 Players Mergers & Acquisitions, Expansion Plans

2.5 United States Cancer Biomarkers Market Size by Company

2.5.1 Top United States Cancer Biomarkers Player s Ranked by Revenue (2023)

2.5.2 United States Cancer Biomarkers Revenue by Player (2018-2023)

3 Cancer Biomarkers Market Segment by Type

3.1 Cancer Biomarkers Market Segment by Type

3.2 Global Cancer Biomarkers Market Size by Type

3.3 United States Cancer Biomarkers Market Size by Type

4 Cancer Biomarkers by Market Segment Application

4.1 Cancer Biomarkers Market Segment by Application

4.2 Global Cancer Biomarkers Market Size by Application

4.3 United States Cancer Biomarkers Market Size by Application

5 Global Cancer Biomarkers Market Size by Region

5.1 Global Cancer Biomarkers Market Size by Region: 2018 VS 2023 VS 2029

5.2 Global Cancer Biomarkers Market Size in Value by Region (2018-2029)

5.2.1 Global Cancer Biomarkers Revenue by Region: 2018-2023

5.2.2 Global Cancer Biomarkers Revenue by Region: 2023-2029

6 Segment in Regional Level & Country Level

6.1 North America

6.1.1 North America Cancer Biomarkers Market Size YoY Growth 2018-2029

6.1.2 North America Cancer Biomarkers Market Facts & Figures by Country (2018-2029)

6.1.3 U.S.

6.1.4 Canada

6.2 Asia Pacific

6.2.1 Asia Pacific Cancer Biomarkers Market Size YoY Growth 2018-2029

6.2.2 Asia Pacific Cancer Biomarkers Market Facts & Figures by Country (2018-2029)

6.2.3 China

6.2.4 Japan

6.2.5 South Korea

6.2.6 India

6.2.7 Australia

6.2.8 Southeast Asia

6.3 Europe

6.3.1 Europe Cancer Biomarkers Market Size YoY Growth 2018-2029

6.3.2 Europe Cancer Biomarkers Market Facts & Figures by Country (2018-2029)

6.3.3 Germany

6.3.4 France

6.3.5 UK

6.3.6 Italy

6.3.7 Russia

6.4 Latin America

6.4.1 Latin America Cancer Biomarkers Market Size YoY Growth 2018-2029

6.4.2 Latin America Cancer Biomarkers Market Facts & Figures by Country (2018-2029)

6.4.3 Mexico

6.4.4 Brazil

6.4.5 Argentina

6.5 Middle East and Africa

6.5.1 Middle East and Africa Cancer Biomarkers Market Size YoY Growth 2018-2029

6.5.2 Middle East and Africa Cancer Biomarkers Market Facts & Figures by Country (2018-2029)

6.5.3 Turkey

6.5.4 Saudi Arabia

6.5.5 UAE

7 Company Profiles

7.1 F. Hoffmann-La Roche Ltd. (Switzerland)

7.1.1 Company Details

7.1.2 Description and Business Overview

7.1.3 Cancer Biomarkers Introduction

7.1.4 F. Hoffmann-La Roche Ltd. (Switzerland) Cancer Biomarkers Revenue, Gross, and Gross Margin (2018-2023)

7.1.5 F. Hoffmann-La Roche Ltd. (Switzerland) Recent Development

7.2 Thermo Fisher Scientific Inc. (U.S.)

7.2.1 Company Details

7.2.2 Description and Business Overview

7.2.3 Cancer Biomarkers Introduction

7.2.4 Thermo Fisher Scientific Inc. (U.S.) Cancer Biomarkers Revenue, Gross, and Gross Margin (2018-2023)

7.2.5 Thermo Fisher Scientific Inc. (U.S.) Recent Development

7.3 Abbott (U.S.)

7.3.1 Company Details

7.3.2 Description and Business Overview

7.3.3 Cancer Biomarkers Introduction

7.3.4 Abbott (U.S.) Cancer Biomarkers Revenue, Gross, and Gross Margin (2018-2023)

7.3.5 Abbott (U.S.) Recent Development

7.4 QIAGEN (Germany)

7.4.1 Company Details

7.4.2 Description and Business Overview

7.4.3 Cancer Biomarkers Introduction

7.4.4 QIAGEN (Germany) Cancer Biomarkers Revenue, Gross, and Gross Margin (2018-2023)

7.4.5 QIAGEN (Germany) Recent Development

7.5 PerkinElmer, Inc. (U.S.)

7.5.1 Company Details

7.5.2 Description and Business Overview

7.5.3 Cancer Biomarkers Introduction

7.5.4 PerkinElmer, Inc. (U.S.) Cancer Biomarkers Revenue, Gross, and Gross Margin (2018-2023)

7.5.5 PerkinElmer, Inc. (U.S.) Recent Development

7.6 Merck KGaA (Germany)

7.6.1 Company Details

7.6.2 Description and Business Overview

7.6.3 Cancer Biomarkers Introduction

7.6.4 Merck KGaA (Germany) Cancer Biomarkers Revenue, Gross, and Gross Margin (2018-2023)

7.6.5 Merck KGaA (Germany) Recent Development

7.7 Bio-Rad Laboratories, Inc. (U.S.)

7.7.1 Company Details

7.7.2 Description and Business Overview

7.7.3 Cancer Biomarkers Introduction

7.7.4 Bio-Rad Laboratories, Inc. (U.S.) Cancer Biomarkers Revenue, Gross, and Gross Margin (2018-2023)

7.7.5 Bio-Rad Laboratories, Inc. (U.S.) Recent Development

7.8 Enzo Biochem, Inc. (U.S.)

7.8.1 Company Details

7.8.2 Description and Business Overview

7.8.3 Cancer Biomarkers Introduction

7.8.4 Enzo Biochem, Inc. (U.S.) Cancer Biomarkers Revenue, Gross, and Gross Margin (2018-2023)

7.8.5 Enzo Biochem, Inc. (U.S.) Recent Development

7.9 Charles River Laboratories (U.S.)

7.9.1 Company Details

7.9.2 Description and Business Overview

7.9.3 Cancer Biomarkers Introduction

7.9.4 Charles River Laboratories (U.S.) Cancer Biomarkers Revenue, Gross, and Gross Margin (2018-2023)

7.9.5 Charles River Laboratories (U.S.) Recent Development

7.10 Eurofins Scientific (Luxembourg)

7.10.1 Company Details

7.10.2 Description and Business Overview

7.10.3 Cancer Biomarkers Introduction

7.10.4 Eurofins Scientific (Luxembourg) Cancer Biomarkers Revenue, Gross, and Gross Margin (2018-2023)

7.10.5 Eurofins Scientific (Luxembourg) Recent Development

7.11 Agilent Technologies, Inc. (U.S.)

7.11.1 Company Details

7.11.2 Description and Business Overview

7.11.3 Cancer Biomarkers Introduction

7.11.4 Agilent Technologies, Inc. (U.S.) Cancer Biomarkers Revenue, Gross, and Gross Margin (2018-2023)

7.11.5 Agilent Technologies, Inc. (U.S.) Recent Development

7.12 Bruker (U.S.)

7.12.1 Company Details

7.12.2 Description and Business Overview

7.12.3 Cancer Biomarkers Introduction

7.12.4 Bruker (U.S.) Cancer Biomarkers Revenue, Gross, and Gross Margin (2018-2023)

7.12.5 Bruker (U.S.) Recent Development

7.13 Siemens (U.S.)

7.13.1 Company Details

7.13.2 Description and Business Overview

7.13.3 Cancer Biomarkers Introduction

7.13.4 Siemens (U.S.) Cancer Biomarkers Revenue, Gross, and Gross Margin (2018-2023)

7.13.5 Siemens (U.S.) Recent Development

7.14 Epigenomics AG (Germany)

7.14.1 Company Details

7.14.2 Description and Business Overview

7.14.3 Cancer Biomarkers Introduction

7.14.4 Epigenomics AG (Germany) Cancer Biomarkers Revenue, Gross, and Gross Margin (2018-2023)

7.14.5 Epigenomics AG (Germany) Recent Development

7.15 General Electric (U.S.)

7.15.1 Company Details

7.15.2 Description and Business Overview

7.15.3 Cancer Biomarkers Introduction

7.15.4 General Electric (U.S.) Cancer Biomarkers Revenue, Gross, and Gross Margin (2018-2023)

7.15.5 General Electric (U.S.) Recent Development

8 Value Chain and Sales Channels Analysis

8.1 Cancer Biomarkers Value Chain Analysis

8.2 Cancer Biomarkers Customers

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology

10.1.1 Research Process

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Legal Disclaimer

Tables & Figures:
Show more
Research Methodology:
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.
Global and United States Cancer Biomarkers Market Size Estimation

To estimate market size and trends, we use a combination of top-down and bottom-up methods. This allows us to evaluate the market from various perspectives—by company, region, product type, and end users.

Our estimates are based on actual sales data, excluding any discounts. Segment breakdowns and market shares are calculated using weighted averages based on usage rates and average prices. Regional insights are determined by how widely a product or service is adopted in each area.

Key companies are identified through secondary sources like industry reports and company filings. We then verify revenue estimates and other key data points through primary research, including interviews with industry experts, company executives, and decision-makers.

We take into account all relevant factors that could influence the market and validate our findings with real-world input. Our final insights combine both qualitative and quantitative data to provide a well-rounded view. Please note, these estimates do not account for unexpected changes such as inflation, economic downturns, or policy shifts.

Data Source

Secondary Sources

This study draws on a wide range of secondary sources, including press releases, annual reports, non-profit organizations, industry associations, government agencies, and customs data. We also referred to reputable databases and directories such as Bloomberg, Wind Info, Hoovers, Factiva, Trading Economics, Statista, and others. Additional references include investor presentations, company filings (e.g., SEC), economic data, and documents from regulatory and industry bodies.

These sources were used to gather technical and market-focused insights, identify key players, analyze market segmentation and classification, and track major trends and developments across industries.

Market Size
  • Segmental value
  • Geographic Penetration
  • Product Adoption Rate for Different market
  • Journals, Websites, and Press Releases
  • Annual Reports and SEC Filings
  • Company Websites and Press Releases
  • Public and Paid Databases
  • Market Intellix Data Repository
Market Position of Top Company
  • Product Financials
  • Geographic value Mix
  • Total Company value
  • Business/Segmental value Mix
Qualitative Analysis
  • Influence Factors
  • Market Potential
  • Market Risks and Opportunities
  • Industry Trends
  • Geographical Features
  • Government Policies
  • Company Websites and Press Releases
  • Public and Paid Databases
  • Annual Reports
  • Industry Associations
  • Market Intellix Data Repository

Primary Sources

As part of our primary research, we interviewed a variety of stakeholders from both the supply and demand sides to gather valuable qualitative and quantitative insights.

On the supply side, we spoke with product manufacturers, competitors, industry experts, research institutions, distributors, traders, and raw material suppliers. On the demand side, we engaged with business leaders, marketing and sales heads, technology and innovation directors, supply chain executives, and end users across key organizations.

These conversations helped us better understand market segmentation, pricing, applications, leading players, supply chains, demand trends, industry outlook, and key market dynamics—including risks, opportunities, barriers, and strategic developments.

Key Data Information from Primary Sources

Primary Sources Parameters Key Data
Market Segments(by Application, by Type)
  • Value by Type
  • Status and Forecast
  • Value by Application
  • Value by Regions, Status and Forecast (2025-2031)
  • Value Market Share by Type
  • Value Growth Rate by Type
  • Value by Application
  • Percentage and Growth Rate by Application
  • Value Growth Rate and Market Share by Regions
  • Market Size Status and Forecast (2025-2031)
Total Market
  • Overall Size, Status and Forecast
  • Market Size Status and Forecast (2025-2031)
Frequently asked questions(FAQ's):
What trends are influencing the growth of the Global and United States Cancer Biomarkers Market?
New players are entering the Global and United States Cancer Biomarkers Market, while established companies are changing their business models and strategies. This pattern is likely to continue for the foreseeable future.
What is the expected rate of growth in the Global and United States Cancer Biomarkers Market?
From 2025 to 2030, the Global and United States Cancer Biomarkers Market is expected to grow at a compound annual growth rate of YY%, reaching a value of USD XXX Million.
What are the advantages of the Global and United States Cancer Biomarkers Market research study?
The Global and United States Cancer Biomarkers Market research study aids businesses in strategic planning so that they may realize and gain business value from their growth strategies.
Who should consider the Global and United States Cancer Biomarkers Market study?
The Global and United States Cancer Biomarkers Industry stakeholders, executives, and experts, as well as individuals who need to develop consumer-friendly strategies and use technology to stay ahead of the competition.